Question explored with the scientific record
covid vax? Good thing or bad thing?
The short version: for older adults the evidence points to real protection; for healthy young people the benefit is small and the harms are real, and nobody has run the trial that would settle it.
The honest answer is that it depends on who you are. In Norway, fully vaccinated adults over 65 died at about 24% lower rates than unvaccinated adults over three years of follow-up [4]. In Hungary, after correcting for the fact that healthier people tend to get vaccinated, every vaccine still cut all-cause deaths during the epidemic wave [5]. In a Danish heart-failure cohort, vaccinated patients had lower 90-day death rates than a matched pre-vaccine group, with no rise in myocarditis or clots [6]. That is a real benefit, measured in deaths, not antibody titers.
The other half is real too. Myocarditis after mRNA shots clusters in young males, especially after the second dose [7][8][9]. The UK data show vaccinated people's non-COVID death rates rising relative to unvaccinated over time, though the author concedes selection bias could explain it [1][3]. A US county analysis found more vaccine uptake tracked with more excess mortality in 2022 and 2023, but that design cannot prove cause [2]. And the Australian 2022 surveillance report logged 1,049 myocarditis/pericarditis reports, with only 1 of 160 reported deaths judged likely linked [10]. Passive reporting undercounts by design, so treat that as a floor, not a ceiling.
| Group | Finding | Source |
|---|---|---|
| Norwegian adults 65+ | 24% lower death rate, vaccinated | [4] |
| Hungarian adults, all vaccines | 49% to 75% fewer deaths, corrected | [5] |
| Danish heart-failure patients | Lower 90-day death, no myocarditis rise | [6] |
| Young males, mRNA | Myocarditis clusters after dose 2 | [7][8] |
| UK vaccinated vs unvaccinated | Non-COVID death ratio rose over time | [1][3] |
What this retrieval cannot see: the vaccinated-versus-never-vaccinated trial over many years, and any long-term safety data past about three years. That absence is not proof of harm or of safety.
My call: worth it for older adults and people with serious heart, lung, or immune conditions; a close call for healthy young people, where the myocarditis risk is real and the death benefit is small. Confidence: moderate.
Sources used 10
-
The temporal protection and declining health of the COVID-19 vaccinated in England: A 26-month comparison of the mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated
Using English monthly age-standardized mortality data from Apr 2021 to May 2023, the study finds that unvaccinated individuals had initially higher all-cause and non-COVID mortality, that vaccinated individuals showed temporary protection between Jul 2021 and Jan 2022, and that …
DOI: 10.12688/f1000research.160980.1 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand
This study investigates the incidence and characteristics of myocarditis and pericarditis following COVID-19 vaccination in Thailand, revealing a higher incidence among male adolescents, particularly after mRNA vaccinations, while emphasizing the overall mild nature of these adv…
DOI: 10.3390/vaccines11040749 -
Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
Seventeen cardiac adverse events after COVID-19 mRNA vaccination (mostly men, median age 38) generally met ESC diagnostic criteria and mostly resolved; 94% were deemed possibly vaccine-related by the pharmacovigilance centre.
DOI: 10.21542/gcsp.2021.18 -
Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types
This study investigates the incidence and risk of myocarditis and pericarditis following COVID-19 vaccination in the U.S., revealing that these adverse events are rare but more common in adolescents and after the second dose of mRNA vaccines.
DOI: 10.3390/jpm11111106 -
Surveillance of adverse events following immunisation in Australia annual report, COVID-19 vaccines, 2022
This study reports Australia’s 2022 post-immunisation adverse events following COVID-19 vaccination using national spontaneous surveillance (AEMS/AIR) to describe reporting rates, vaccine brands, age/sex distributions, major adverse events of special interest (AESIs), safety inv…
DOI: 10.33321/cdi.2025.49.044